Klein F, Juhl B, Christiansen J S
Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Kommunehospital, Denmark.
Scand J Clin Lab Invest. 1995 Feb;55(1):53-9. doi: 10.3109/00365519509075378.
The object of the study was to test whether high dose ascorbic acid (AA) could normalize glomerular hyperfiltration in insulin-dependent diabetes mellitus (IDDM) patients. A prospective, double-blind, randomized, placebo (tartaric acid, TA) controlled study design was used, with parallel treatment lasting 4 weeks. Measurements were made before and after treatment, on 24 normoalbuminuric, normotensive male IDDM patients, who were randomized to ascorbic acid (n = 12, age 35 years (18-39), diabetes duration 12 years (2-12), BP 128/82 mmHg (SD 14/6)), or to placebo (TA) (n = 12, age 30 years (19-36), diabetes duration 8 years (2-17), BP 119/75 mmHg (SD 9/7). The intervention consisted of 6 enterosoluble tablets of 500 mg AA or 213 mg TA, twice a day, being daily doses of 6 g AA or 2.55 g TA. No significant differences in any of the parameters measured were seen, when comparing results following AA or placebo treatment. The glomerular filtration rate (GFR, clearance of 125I-iothalamate) was unchanged while effective renal plasma flow (ERPF, clearance of 131I-hippuran) tended to decline in both groups. The GFRs before and after treatment in the AA-treated group were 141 (SD 15) and 134 (SD 12) ml min-1 1.73 m-2; NS (2p = 0.09). In the TA-treated group they were 142 (SD 19) and 137 (SD 16) ml min-1 1.73 m-2; NS (2p = 0.20). The ERPFs in the AA group were 584 (SD 93) and 545 (SD 47) ml min-1 1.73 m-2; (2p = 0.06). In the TA group they were 618 (SD 108) and 574 (SD 98) ml min-1 1.73 m-2 (2p = 0.03). The filtration fractions (FFs) in the AA group were 0.244 and 0.246 NS.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是测试高剂量抗坏血酸（AA）能否使胰岛素依赖型糖尿病（IDDM）患者的肾小球高滤过恢复正常。采用前瞻性、双盲、随机、安慰剂（酒石酸，TA）对照的研究设计，平行治疗持续4周。对24名正常白蛋白尿、血压正常的男性IDDM患者在治疗前后进行测量，这些患者被随机分为抗坏血酸组（n = 12，年龄35岁（18 - 39岁），糖尿病病程12年（2 - 12年），血压128/82 mmHg（标准差14/6））或安慰剂（TA）组（n = 12，年龄30岁（19 - 36岁），糖尿病病程8年（2 - 17年），血压119/75 mmHg（标准差9/7））。干预措施为每天两次服用6片500 mg的AA肠溶片或213 mg的TA肠溶片，即每日剂量为6 g AA或2.55 g TA。比较AA或安慰剂治疗后的结果时，未发现所测任何参数有显著差异。两组的肾小球滤过率（GFR，125I - 碘肽酸盐清除率）均未改变，而有效肾血浆流量（ERPF，131I - 马尿酸清除率）均有下降趋势。AA治疗组治疗前后的GFR分别为141（标准差15）和134（标准差12）ml·min⁻¹·1.73 m⁻²；无显著差异（P = 0.09）。TA治疗组的GFR分别为142（标准差19）和137（标准差16）ml·min⁻¹·1.73 m⁻²；无显著差异（P = 0.20）。AA组的ERPF分别为584（标准差93）和545（标准差47）ml·min⁻¹·1.73 m⁻²；（P = 0.06）。TA组的ERPF分别为618（标准差108）和574（标准差98）ml·min⁻¹·1.73 m⁻²（P = 0.03）。AA组的滤过分数（FFs）分别为0.244和0.246，无显著差异。（摘要截断于250字）
